Friday, December 6, 2019

FORHP Special Announcement - New Federal Funding for Black Lung Clinics Program

FORHP Header with Logos

December 6, 2019

New Federal Funding Opportunity for the Black Lung Clinics Program and Black Lung Data and Resource Center Program 

The Health Resources and Services Administration (HRSA) published the Notice of Funding Opportunity (NOFO) for the FY 2020 Black Lung Clinics Program (BLCP). The purpose of this program is to reduce the morbidity and mortality associated with occupationally-related coal mine dust lung disease through the provision of quality medical, outreach, educational, and benefits counseling services for active, inactive, retired, and disabled US coal miners. The FY 2020 BLCP NOFO reflects current disease trends and incorporates language around Coal Workers' Pneumoconiosis and Progressive Massive Fibrosis to increase educational and outreach activities and promote early detection. The NOFO also extends the competitive cycle from three years to five years and requires patient-level data reporting.  This will allow HRSA to longitudinally track disease progression in miner patients to better inform medical, outreach, educational, and benefits counseling services provided. It is anticipated that up to 15 grant awards will be made.

Also published today is the NOFO for the Black Lung Data and Resource Center (BLDRC) which is focused on strengthening the operations of BLCP recipients through programmatic assistance and improved data collection and analysis related to the health status and needs of U.S. coal miners. It is anticipated that up to one cooperative agreement award will be made.

Full details on both programs and requirements for applicants are available at Grants.gov.  For questions about either program, contact Krista M. Mastel at blacklung@hrsa.gov.

The application deadline is March 6, 2020.


This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: HRSA · 5600 Fishers Lane · Rockville, MD 20857  GovDelivery logo

KRAS Inhibitor Shows Promise in Early Trial - Cancer Currents Blog

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

12/05/2019
An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in cancer mouse models and data from a small clinical trial show that it appears to be active against different cancer types with a KRAS mutation.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

2020 National Nutrition & Aging Services Conference Call for Proposals

Having trouble viewing this email? View it as a Web page.

From Our Partners

December 6, 2019

2020 National Nutrition & Aging Services Conference Call for Proposals

The National Association of Nutrition and Aging Services Programs (NANASP) invites you to share your nutrition, senior center, and aging services expertise, research, and promising practices by submitting a presentation proposal for their 2020 Annual Training Conference on June 3-5, 2020 at the AT&T Conference Center in Austin, TX. 

For more information visit the conference website before December 11.


Back to top

FacebookTwitterYoutube

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: Administration for Community Living
·330 C Street SW  · Washington, D.C. 20001
GovDelivery logo

Thursday, December 5, 2019

Gay, bisexual men increasingly agree: HIV “Undetectable Equals Untransmittable”

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

 

12/05/2019 02:00 PM EST

Yet transmission-risk misunderstandings persist, finds large NIH-supported study.

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612 GovDelivery logo

NIDCR E-Newsletter: Winter 2019

News from NIDCR, NIH/HHS, Science Advances, Funding Opportunities

Having trouble viewing this email? View it as a Web page.

E-Newsletter Header

NIDCR's Winter 2019 E-Newsletter is now available.

In this issue:


This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Dental and Craniofacial Research · 9000 Rockville Pike · Bethesda, MD 20892 GovDelivery logo

Gay, Bisexual Men Increasingly Agree: HIV “Undetectable Equals Untransmittable”

NIAID Logo

Friday, December 5, 2019

Gay, Bisexual Men Increasingly Agree: HIV "Undetectable Equals Untransmittable"

U=U slogan over pills used to treat HIV

Yet Transmission-Risk Misunderstandings Persist, Finds Large NIH-Supported Study

Extensive evidence from HIV prevention research studies has firmly established that "Undetectable Equals Untransmittable," or U=U. This means that people living with HIV who achieve and maintain an undetectable viral load—the amount of virus in their blood—by taking antiretroviral therapy as prescribed do not sexually transmit HIV to others. The U.S. Centers for Disease Control and Prevention estimates this strategy is 100% effective against the sexual transmission of HIV.

Now, a new study of nearly 112,000 men who have sex with men in the United States has found increasing acceptance of the U=U message in this population. Overall, 54% of HIV-negative participants and 84% of participants with HIV correctly identified U=U as accurate. Study results were published online today in the Journal of Acquired Immune Deficiency Syndromes.

Read More


This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107 GovDelivery logo

Scientific/Clinical and Community Member Nominations Are Now Being Accepted for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

 

 

 

     
   
 
 

At-a-Glance

 
Issue No. 29 | December 5, 2019 View HTML version
 
 
News and Features

Scientific/Clinical Member Nominations Are Now Being Accepted for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in:
  • HIV clinical research and clinical care
  • Clinical pharmacology (with emphasis on expertise in antiretroviral-related drug-drug interactions)
  • Clinical nursing in HIV

Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 4-year term beginning May 2020, with potential for reappointment for an additional term.


The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.


Panel members are not financially compensated for their time commitment.


The nomination should include a curriculum vitae and a letter of interest or a letter of nomination (from a colleague) with specific reference to how the nominee would contribute to the work of the Panel, especially in the areas noted above. Self-nomination is welcome. All supporting documents should be submitted to Alice Pau, Pharm.D., electronically (apau@niaid.nih.gov) by no later than January 10, 2020.



Community Member Nominations Are Now Being Accepted for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for a community representative to serve a 4-year term beginning May 2020, with potential for reappointment for one additional term. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he/she represents. The candidate shall have knowledge and involvement in issues related to the management of adults and adolescents living with HIV, as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment.


The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. The guideline is a living document.


Panel members are not financially compensated for their time commitment.


The nomination should include a resume and a letter of nomination or a letter of interest with specific reference as to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Alice Pau, Pharm.D., electronically (apau@niaid.nih.gov) by no later than January 10, 2020.



 
 
     
 
Home | Guidelines | Understanding HIV/AIDS | Drugs | Clinical Trials | Research
Contact Us
 
 
     

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: AIDSinfo · P.O. Box 4780· Rockville, MD 20849-6303 GovDelivery logo